What SEC filings does AN2 Therapeutics, Inc. submit to the SEC?

AN2 Therapeutics, Inc. (ANTX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ANTX?

A Form 4 for ANTX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from AN2 Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ANTX?

The 10-K is AN2 Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ANTX SEC filings directly on EDGAR?

You can view all historical AN2 Therapeutics, Inc. filings on the SEC EDGAR company page for ANTX. Each filing card on this page links directly to the original SEC document.

How often does AN2 Therapeutics, Inc. file with the SEC?

AN2 Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ANTX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ANTX SEC Filing News — AN2 Therapeutics, Inc.

Latest SEC filings for AN2 Therapeutics, Inc. (ANTX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-16.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chag…

Sector: Healthcare Industry: Biotechnology Market Cap: $124.2M CIK: 1880438

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for ANTX currently lean bearish. Of the 12 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

ANTX Filing Activity Snapshot 2026-07-10 — 2026-09-16

Insider Transactions (Form 4)

1 buy vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$6.08M

Readnour Robin Shane · 2026-08-17

1,012,000 shares · Form 144

Form 144 Notices

Proposed insider sale filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for AN2 Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 4 open-market sale, 3 compensation award, 1 gift and 1 open-market purchase. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×3: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Compensation award Tax / Compensation Filing 2026-09-16

ANTX insider Form 4 filed for equity award, exercise, or tax withholding

Trenor Cameron C. III (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	116,667	—	—
`A`	Compensation award derivative · Stock Option (right to by)	233,333	—	—

Filing: Form 4 (Insider Transaction) Insider: Trenor Cameron C. III (Chief Medical Officer) Shares: 116,667

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-11

ANTX insider Readnour Robin Shane (Director) sold 1,108 shares (~$6.7K)

Readnour Robin Shane, listed as Director at AN2 Therapeutics, Inc., reported an open-market sale of 1,108 ANTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	523	$6.02	$3.2K
`S`	Open-market sale	585	$6.02	$3.5K

Filing: Form 4 (Insider Transaction) Insider: Readnour Robin Shane (Director) Shares: 1,108 Est. Value: $6.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-08

ANTX insider Readnour Robin Shane (Director) sold 16,119 shares (~$97.3K)

Readnour Robin Shane, listed as Director at AN2 Therapeutics, Inc., reported an open-market sale of 16,119 ANTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,877	$6.07	$17.5K
`S`	Open-market sale	3,223	$6.07	$19.6K
`S`	Open-market sale	4,725	$6.02	$28.4K
`S`	Open-market sale	5,294	$6.02	$31.9K

Filing: Form 4 (Insider Transaction) Insider: Readnour Robin Shane (Director) Shares: 16,119 Est. Value: $97.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-04

ANTX insider Williams Sarah Joanne (Principal Accounting Officer) sold 272 shares (~$1.5K)

Williams Sarah Joanne, listed as Principal Accounting Officer at AN2 Therapeutics, Inc., reported an open-market sale of 272 ANTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	272	$5.53	$1.5K

Filing: Form 4 (Insider Transaction) Insider: Williams Sarah Joanne (Principal Accounting Officer) Shares: 272 Est. Value: $1.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-02

ANTX insider FitzPatrick Margaret M (Director) bought 2,098 shares (~$11.6K)

FitzPatrick Margaret M, listed as Director at AN2 Therapeutics, Inc., reported an open-market purchase of 2,098 ANTX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	2,098	$5.53	$11.6K

Filing: Form 4 (Insider Transaction) Insider: FitzPatrick Margaret M (Director) Shares: 2,098 Est. Value: $11.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-19

ANTX insider Readnour Robin Shane (Director) sold 35,402 shares (~$212.7K)

Readnour Robin Shane, listed as Director at AN2 Therapeutics, Inc., reported an open-market sale of 35,402 ANTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	16,696	$6.01	$100.3K
`S`	Open-market sale	18,706	$6.01	$112.4K

Filing: Form 4 (Insider Transaction) Insider: Readnour Robin Shane (Director) Shares: 35,402 Est. Value: $212.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-08-14

ANTX insider Form 4 filed for equity award, exercise, or tax withholding

Zakrzewski Joseph S (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	405,880	—	—

Filing: Form 4 (Insider Transaction) Insider: Zakrzewski Joseph S (Director) Shares: 405,880

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-10

ANTX insider Form 4 filed for equity award, exercise, or tax withholding

Aziz Kabeer (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,852	—	—

Filing: Form 4 (Insider Transaction) Insider: Aziz Kabeer (Director) Shares: 2,852

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-10

ANTX insider Form 4 filed for equity award, exercise, or tax withholding

Marks Gilbert Lynn (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	2,789	—	—

Filing: Form 4 (Insider Transaction) Insider: Marks Gilbert Lynn (Director) Shares: 2,789

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. AN2 Therapeutics, Inc. has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Large Proposed Insider Sale 2026-08-17

ANTX Form 144 filed for proposed insider sale by Readnour Robin Shane (1,012,000 shares) ~$6.08M

Readnour Robin Shane filed a Form 144 with the SEC indicating intent to sell ANTX (AN2 Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Readnour Robin Shane Shares: 1,012,000 Est. Value: $6.08M

View on SEC EDGAR → Open Filing Document →

Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for AN2 Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-11

ANTX filed 8-K — material company event

AN2 Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for AN2 Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-11

ANTX filed Quarterly Report (10-Q)

AN2 Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify AN2 Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on ANTX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — ANTX SEC Filings

More Tools for ANTX

ANTX Full Stock Analysis ANTX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper ANTX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the ANTX stock analysis page.

ANTX Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer